Literature DB >> 17155899

Implications of cancer stem cells in the treatment of cancer.

Chong-Xian Pan1, Wei Zhu, Liang Cheng.   

Abstract

Identification of cancer stem cells (CSCs) in both hematological and solid malignancies suggests that CSCs may be a common phenomenon for most malignancies. Similarly to normal stem cells, CSCs can self-renew and differentiate into progeny cancer cells. Almost all current therapy against cancer targets differentiated cancer cells. CSCs are more resistant to therapy secondary to quiescence, increased expression of antiapoptotic proteins and drug efflux transporters. In this article, we review the current status of CSC research and propose the targeting of CSC cell-surface molecules, signal transduction pathways, the stem cell niche, stem cell differentiation and drug resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17155899     DOI: 10.2217/14796694.2.6.723

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  6 in total

Review 1.  Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Authors:  Ameya R Kirtane; Stephen M Kalscheuer; Jayanth Panyam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-10       Impact factor: 15.470

2.  Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.

Authors:  Hongyong Zhang; Yuanpei Li; Tzu-Yin Lin; Kai Xiao; Ashraf S Haddad; Paul T Henderson; Brian A Jonas; Mingyi Chen; Wenwu Xiao; Ruiwu Liu; Kit S Lam; Chong-xian Pan
Journal:  Nanomedicine (Lond)       Date:  2014-03-17       Impact factor: 5.307

3.  Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.

Authors:  Hongyong Zhang; Juntao Luo; Yuanpei Li; Paul T Henderson; Yanchun Wang; Sebastian Wachsmann-Hogiu; Weixin Zhao; Kit S Lam; Chong-xian Pan
Journal:  Nanomedicine       Date:  2011-12-23       Impact factor: 5.307

4.  Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

Authors:  M Bartucci; S Svensson; P Romania; R Dattilo; M Patrizii; M Signore; S Navarra; F Lotti; M Biffoni; E Pilozzi; E Duranti; S Martinelli; C Rinaldo; A Zeuner; M Maugeri-Saccà; A Eramo; R De Maria
Journal:  Cell Death Differ       Date:  2011-11-25       Impact factor: 15.828

Review 5.  Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications.

Authors:  Minal Vaish
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

6.  Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells.

Authors:  Dong-Cheol Seo; Ji-Min Sung; Hee-Jung Cho; Hee Yi; Kun-Ho Seo; In-Soo Choi; Dong-Ku Kim; Jin-Suk Kim; Abd El-Aty AM; Ho-Chul Shin
Journal:  Mol Cancer       Date:  2007-11-22       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.